Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06429839

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Nimotuzumab Concurrent With Chemoradiotherapy for Elderly or Malnourished Patients With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Chemoradiotherapy Chemotherapy Esophageal Cancer Immunotherapy Nimotuzumab

Interventions Nimotuzumab with chemoradiotherapy

Updated 3 times since 2024 Last updated: May 21, 2024 Started: Mar 1, 2023 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06429839, this PHASE2 trial focuses on Chemoradiotherapy and Chemotherapy and remains actively recruiting participants. Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, it has been updated 3 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China